GlassScriptPhysician profile
Matthew Morello
NPI 1699770883
$6,830.26
in general payments reported to CMS, 2019-2025
23 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $357 · 2021: $833 · 2022: $1,141 · 2023: $1,221 · 2024: $1,124 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,686.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,370.82 | 2019-2025 | Cequa |
| Abbvie INC. | $1,037.43 | 2022-2025 | |
| Alcon Vision LLC | $1,037.24 | 2019-2025 | Clareon, Wavelight Refractive Suite, Total30 |
| Novartis Pharmaceuticals Corporation | $537.47 | 2019-2023 | |
| Allergan, INC. | $362.78 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $352.96 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $349.40 | 2022-2025 | Infuse, Xiidra, Miebo |
| Oyster Point Pharma, INC. | $303.30 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $257.75 | 2024-2025 | Vevye |
| Dompe US, INC. | $216.45 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $164.92 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $115.90 | 2022 | |
| Thea Pharma INC. | $105.05 | 2022-2025 | Iyuzeh |
| Carl Zeiss Meditec, INC. | $99.15 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.55 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $79.95 | 2019 | |
| Biotissue Holdings INC. | $78.23 | 2019-2025 | |
| Optos, INC. | $76.09 | 2019 | |
| Coopervision INC. | $53.42 | 2021-2025 | Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $45.65 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $41.61 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $37.59 | 2021 | |
| Genentech USA, INC. | $26.55 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Morello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.